Physician
Obstetrics & Gynecology
Dr. Mack N. Barnes III, MD
|
|
Give Review
Mack N. Barnes III, MD works in the field of Obstetrics & Gynecology. He studied medicine at University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is one of the top medical schools in the US. University of North Carolina at Chapel Hill School of Medicine has a rank of 22 in research and a 2 in primary care He received awards:"Fellow (FACOG)". Dr. Mack N. Barnes III is a published physician as well. He has 72 publications published. The latest was: Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. He is registered with Medicare.
Publications
- Perioperative Morbidity and Mortality in Octogenarians With Ovarian Cancer.
- A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell Carcinoma of the vulva: A gynecologic oncol...
- Phase II trial of bevacizumab in recurrent or persistent endometrial Cancer: a Gynecologic Oncology Group study.
- Assessment of Risk Factors for 30-Day Hospital Readmission After Surgical Cytoreduction in Epithelial Ovarian Carcinoma.
- A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic Diseases.
- Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with re...
- A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian Carcinoma.
- Expression of c-kit and platelet-derived growth factor receptors in Ovarian granulosa cell tumors.
- Lynch syndrome in women less than 50 years of age with endometrial Cancer.
- Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian Cancer patients.
- A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian Carcinoma following the failure of second-line therapy.
- Bowel resection at the time of primary debulking for epithelial ovarian Carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
- The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian Carcinoma.
- Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian Cancer.
- Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
- Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian Cancer ...
- A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of Pelvic masses.
- Feasibility of performing chemoprevention trials in women at elevated risk of ovarian Carcinoma: initial examination of celecoxib as a chemopreventive agent.
- Occult chorioCarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy.
- Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery.
- Protrusio acetabuli presenting as a complex Pelvic mass after total hip arthroplasty.
- The impact of aborted radical hysterectomy in patients with cervical Carcinoma.
- Primary lung large cell Carcinoma metastatic to the vulva: a case report and review of the literature.
- Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
- Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian Carcinoma.
- Stage IC adenoCarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy.
- Primary extrarenal rhabdoid tumor of the ovary. A case report.
- A pilot study of ovarian Cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis.
- A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian Cancer.
- Paradigms for primary prevention of ovarian Carcinoma.
- Gene transfer to ovarian Cancer versus normal tissues with fiber-modified adenoviruses.
- In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.
- Conditionally replicative adenoviruses for ovarian Cancer therapy.
- Treatment of ovarian Cancer with a tropism modified oncolytic adenovirus.
- Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian Carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.
- Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian Cancer cells.
- Cytoplasmic localization of endothelial constitutive nitric oxide synthase in endometrial Carcinomas.
- Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal Status.
- Current strategies in gene therapy for ovarian Cancer.
- Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian Cancer.
- Burkitt lymphoma in pregnancy.
- Complete surgical staging of early endometrial adenoCarcinoma: optimizing patient outcomes.
- Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian Cancer gene therapy.
- Predictors of outcome in small cell Carcinoma of the cervix--a case series.
- Surgical management of endometrial adenoCarcinoma using laparoscopically assisted staging and treatment.
- Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
- Fertility-sparing radical abdominal trachelectomy for clear cell adenoCarcinoma of the upper vagina: a case report.
- Improved survival in non-Ashkenazi Jewish ovarian Cancer patients with BRCA1 and BRCA2 gene mutations.
- Gene therapy for ovarian Carcinoma.
- The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian Carcinoma cell lines.
- Bax-induced apoptosis as a novel gene therapy approach for Carcinoma of the cervix.
- Strategies to accomplish targeted expression of transgenes in ovarian Cancer for molecular therapeutic applications.
- Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian Cancer cell lines.
- An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian Cancer cells and allows imaging of gene expression.
- A comparison of treatment strategies for endometrial adenoCarcinoma: analysis of financial impact.
- Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.
- Epithelial ovarian Cancer: prevention, diagnosis, and treatment.
- Gene therapy and ovarian Cancer: a review.
- Transcriptional targeting for ovarian Cancer gene therapy.
- Adenovirus-mediated soluble FLT-1 gene therapy for ovarian Carcinoma.
- Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian Cancer chemoprevention.
- Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian Carcinoma cells versus autologous mesothelial cells in vitro.
- Adenoviral-mediated suicide gene therapy for ovarian Cancer.
- A Cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
- An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian Cancer.
- Response to salvage treatment in recurrent ovarian Cancer treated initially with paclitaxel and platinum-based combination regimens.
- The secretory leukoprotease inhibitor (SLPI) promoter for ovarian Cancer gene therapy.
- Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian Cancer spheroids.
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian Cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic ...
- p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian Carcinomas.
- Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian Cancer therapy.
Schools
University Of North Carolina Chapel Hill School Of Medicine
University Nc
Northwestern University
University Ala
Procedures Preformed
- Colpopexy
- Colporrhaphy
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Fellow (FACOG)
Education
-
McGaw Medical Center of Northwestern University -
University of North Carolina Hospitals -
University of North Carolina at Chapel Hill School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Lewis R. Schulman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Warner K. Huh, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Charles N. Landen Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cary P. Crowe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel E. Gray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles A. Leath III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Groesbeck P. Parham, MD |
|
|
Dr. John M. Straughn Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Akila Subramaniam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kellie Matthews, MD |
|
|
Dr. James M. Austin Jr., MD |